The pharma sector has been on a stable growth trajectory lately, and the trend gathered momentum when the pandemic-related emergency made companies
Bristol-Myers bets on product pipeline to beat patent issues. Is BMY a buy?
Categories
Health Care
Infographic: How Tilray (TLRY) performed in Q2 2022
Tilray (NASDAQ: TLRY) reported second-quarter 2022 financial results before the regular market hours on Monday. Total net revenue increased 20% year-over-year to
Addex Therapeutics CEO Tim Dyer: There is a $4-bil market opportunity in dyskinesia
Credit:DavidBGray on iStock Tell us a bit about your clinical programs and how they are different from the existing therapies. Addex is
Walgreens Boots Alliance Inc. (WBA) Q1 2022 Earnings Call Transcript
Walgreens Boots Alliance Inc. (NASDAQ: WBA) Q1 2022 earnings call dated Jan. 06, 2022, Call participants: Tiffany Kanaga -- Vice President of
Angiodynamics Inc (ANGO) Q2 2022 Earnings Call Transcript
Angiodynamics Inc (NASDAQ: ANGO) Q2 2022 earnings call dated Jan. 06, 2022 Corporate Participants: Jim Clemmer -- President and Chief Executive Officer
Walgreens Boots Alliance (WBA) Q1 Earnings: Key financials and quarterly highlights
Walgreens Boots Alliance, Inc. (NASDAQ: WBA) reported first quarter 2022 earnings results today. Sales increased 7.8% year-over-year to $33.9 billion. Net earnings
IPO news: Here are a few points to note as Amylyx Pharmaceuticals goes public this week
There are quite a few pharmaceutical companies lined up to make their market debut this week. Among these is Amylyx Pharmaceuticals which
Trxade Health Inc. (NASDAQ: MEDS) Q4 2021 Research Summary
Trxade Health Inc. (NASDAQ: MEDS) is a healthcare service technology platform that mainly serves the secondary pharmaceutical supply chain, offering a web-based
IPO news: What to look for when Vigil Neuroscience goes public this week
As the first week of the new year slowly unfolds, it appears the pharmaceutical industry is taking the front seat in the
Here are 2 top stock picks to enrich your portfolio in the new year
For businesses across the world, 2021 was a special year for many reasons -- a period of great uncertainty due to the
IPO Alert: Key facts about CinCor Pharma’s upcoming market debut
The healthcare sector, led by pharmaceutical and biotechnology firms, has contributed significantly to the IPO boom that sent the market into overdrive
Equillium CEO Bruce Steel: We are among the few evaluated in first-line GVHD treatment
Credit:DavidBGray on iStock What is Equillium all about? We started the company four years ago around our lead drug program itolizumab. My
Rite Aid Corporation (RAD) Q3 2022 Earnings Call Transcript
Rite Aid Corporation (NYSE: RAD) Q3 2022 earnings call dated Dec. 21, 2021 Corporate Participants: Trent Kruse -- Senior Vice President of Investor Relations
HEXO Corp. (HEXO) Q1 2022 Earnings Call
HEXO Corp. (NYSE: HEXO) Q1 2022 earnings call dated Dec. 14, 2021 Corporate Participants: Jennifer Smith — Director, Investor Relations Scott Cooper — President, Chief Executive Officer
HEXO Corp. (HEXO) Q1 2022 Earnings Call Transcript
HEXO Corp. (NYSE: HEXO) Q1 2022 earnings call dated Dec. 14, 2021 Corporate Participants: Jennifer Smith -- Director, Investor Relations Scott Cooper -- President, Chief Executive
Champions Oncology, Inc. (CSBR) Q2 2022 Earnings Call Transcript
Champions Oncology, Inc. (NASDAQ: CSBR) Q2 2022 earnings call dated Dec. 13, 2021. Corporate Participants: Ronnie Morris -- President & Chief Executive Officer David
Merck & Co. (MRK) stock research summary | Q3 2021
Merck is a multinational pharmaceutical company which announced its earnings call on October 28, 2021. Merck beat Zacks consensus on EPS earning
Biofrontera sees TAM of $4 Bln for lead product Ameluz: CEO Erica Monaco
Caption: iStock Biofrontera Inc. (Nasdaq: BFRI) is a biopharmaceutical company providing specialty dermatology therapies and services in the United States. Founded in
Avid Bioservices, Inc. (CDMO) Q2 2022 Earnings Call Transcript
Avid Bioservices, Inc. (NASDAQ: CDMO) Q2 2022 earnings call dated Dec. 07, 2021 Corporate Participants: Tim Brons -- Investor Relations, Vida Strategic Partners Nicholas
HealthEquity, Inc. (HQY) Q3 2021 Earnings Call Transcript
HealthEquity, Inc. (NASDAQ: HQY) Q3 2021 earnings call dated Dec. 06, 2021 Corporate Participants: Richard Putnam -- Investor Relations Jon Kessler -- President/Chief Executive Officer Tyson
Eli Lilly and Company (LLY) Earnings: 3Q21 Key Numbers
Eli Lilly and Company (NYSE: LLY) reported revenue of $6.7 billion for the third quarter of 2021, up 18% year-over-year. Reported net